Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The approval further adds to Biocon’s portfolio of complex drug products
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Subscribe To Our Newsletter & Stay Updated
